Preliminary injunction against MGI Tech GmbH
Oxford Nanopore Technologies plc
16 September 2026
Oxford Nanopore Technologies plc
("Oxford Nanopore" or the "Company")
Unified Patent Court grants preliminary injunction against MGI Tech GmbH relating to CycloneSEQ sequencing platform
16 September 2026
Oxford Nanopore Technologies plc (LSE: ONT), the company delivering a new generation of nanopore‑based molecular sensing, announces that the Munich Local Division of the Unified Patent Court has granted a preliminary injunction against MGI Tech GmbH relating to the CycloneSEQ-WT02, CycloneSEQ- WY01, G100-ER and G400-ER systems and any other sequencer system embodying materially the same sequencing technology (the "Cyclone Sequencing Systems").
The preliminary injunction follows Oxford Nanopore's application for provisional measures claiming that the Cyclone Sequencing Systems infringe two of its patents (EP 2 422 198 and EP 2 715 343).
Under the order, MGI Tech GmbH must refrain from making, offering, placing on the market, using, importing, storing, supplying or offering to supply the Cyclone Sequencing Systems and related flow cells. The injunction applies in Denmark, France, Germany, the Netherlands, Liechtenstein, Switzerland, the United Kingdom and in Ireland (in Ireland injunction is limited to Cyclone Sequencing System used with a flow cell). The order is effective immediately and enforceable pending any appeal.
MGI Tech GmbH is subject to penalty payments for any non-compliance.
Oxford Nanopore will commence proceedings seeking a permanent injunction and the Court has scheduled the trial hearing for October 2027.
Oxford Nanopore remains committed to protecting the intellectual property ("IP") that underpins its nanopore sensing platform. The Company regards its IP, protected through a global patent portfolio and continued investment in innovation, as fundamental to delivering value for customers, partners and shareholders worldwide.
-ENDS-
For further information, please contact:
Oxford Nanopore Technologies plc
Investors: ir@nanoporetech.com
Media: media@nanoporetech.com
About Oxford Nanopore Technologies plc:
Oxford Nanopore Technologies has developed a new generation of nanopore-based sensing technology that is currently used for real-time, high-performance, accessible, and scalable analysis of DNA and RNA. The technology is used in more than 125 countries, to understand the biology of humans, plants, animals, bacteria, viruses and environments as well as to understand diseases such as cancer. Oxford Nanopore's technology also has the potential to provide broad, high impact, rapid insights in a number of areas including healthcare, food and agriculture.
For more information please visit: www.nanoporetech.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
ENDRNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.